Arbikie distillery announces ongoing support for MND
April 2019: £1 per bottle for all sales of Arbikie Distillery's AK’s Gin will go to support MND research and support.
Family-owned, Field-to-Bottle Distiller, Arbikie Distillery has announced that it will be donating £1 per bottle for all on-going sales of their AK’s Gin to support people with MND through the work of The Euan MacDonald Centre for MND Research and MND Scotland.
Arbikie Distillery, which is based on Scotland’s scenic East Coast by Lunan Bay is owned and run by the Stirling brothers, who named their award-winning AK’s Gin after their father, Alex Kirkwood Stirling, who recently passed away after living with MND for a number of years.
The family wanted to celebrate his life and provide an on-going legacy by announcing this charitable donation in April-when he would have been celebrating his 84th birthday. Alex Stirling farmed at Lunan Bay for over 60 years and built a sizeable mixed arable farming enterprise that provided an ideal base for the development of one of the world’s few field-to-bottle distilleries.
The Stirling Brothers already have a close relationship with MND Scotland and the Euan MacDonald Centre for MND Research and will be working with these charities to ensure their fundraising helps all of those affected by MND.
“Our family is keen to support the great work already being done by our partners to support, prevent & cure Motor Neurone Disease whilst also celebrating the life of our father Alex Stirling, a humble and hard-working farmer, who along with our mother gave us a great start to our drinks business and inspires us to create a truly world class family of spirits. Everything that goes into our drinks is grown by our farming business that was built by our mum and dad, and it just seemed an appropriate way to keep dad’s memory alive and to give something back”.
“We are immensely grateful to the Stirling brothers for their support of MND research. Celebrating the life of their father in this way provides a wonderful legacy. It will help us improve quality of life for the people with MND and support drug trials and help us develop new medicines to treat this devastating condition.”